DRGT 104Alternative Names: DRGT-104
Latest Information Update: 08 Dec 2016
At a glance
- Originator Druggability Technologies
- Mechanism of Action Esterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 07 Dec 2016 Preclinical trials in Undefined indication in Hungary (unspecified route)